Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.
about
Multigene assays and molecular markers in breast cancer: systematic review of health economic analysesTowards decision-making using individualized risk estimates for personalized medicine: A systematic review of genomic classifiers of solid tumors.Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting.Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?Genome-based risk prediction for early stage breast cancer.Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?Cost-utility analyses of drug therapies in breast cancer: a systematic review.Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews.A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K.Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer.The application of Oncotype DX in early-stage lymph-node-positive disease.Is individualized medicine more cost-effective? A systematic review.Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.Clinical utility of gene-expression signatures in early stage breast cancer.Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer.Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer.Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment.Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.Spotlight on the utility of the Oncotype DX® breast cancer assay.
P2860
Q26825362-548C745C-0CE3-4DF2-9E9B-384D20BF2911Q30252422-B0E0A01C-DA1F-4068-AB43-A541DBB7B89AQ30543788-D3C836AA-7B38-4E1D-A737-B2F7E23CB11DQ30612258-4A28E0BF-F50A-436F-9180-E37C1E7730C6Q34338152-248C6710-1A7B-495E-A0CC-5AEA8892C452Q34359289-BBA29E1F-229F-4FF9-884B-419BA8035BBFQ34431985-25AB20FD-C6E0-4DF6-840D-BAA40F141588Q35146930-5A58B858-6DDC-4357-AE43-B5EB6B97069BQ36116276-3776961E-9947-4932-92D5-487D694512A4Q36424052-7BA8C58C-AAC1-479A-B439-A1C74CB8A6B2Q36924703-B3B4A7BD-62DC-4A74-A1BC-B6FEEE4B0016Q37659082-FF67E0A4-0D23-459E-9322-261B9012BEA6Q38180001-A7D71F21-08DC-4FAD-A9DB-8FAB55D4CEB7Q38191496-343FBD0C-B974-4FFC-AEE6-F17A1EAA2E08Q38232507-F7C0A515-9013-4435-A72A-4F83D504BF2BQ38754717-F3194677-F420-4205-BA06-45E1F0828680Q39202749-417FF852-DB6D-48F9-999C-E06751603485Q39305209-A6F03217-0AFA-41CF-A3EB-8BBEDF409447Q40420167-9CD4C209-E851-4266-91C0-A912AFDCC7DCQ51039141-B3187058-40A8-4C60-B234-20B8DC5127B7Q52586260-7E8A3FB3-3330-495D-96FC-0D2E34BB5C82Q52728983-C58050E3-D6F5-4806-B308-6FA2A5933DDA
P2860
Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Cost-utility of the 21-gene re ...... d node-positive breast cancer.
@en
Cost-utility of the 21-gene re ...... d node-positive breast cancer.
@nl
type
label
Cost-utility of the 21-gene re ...... d node-positive breast cancer.
@en
Cost-utility of the 21-gene re ...... d node-positive breast cancer.
@nl
prefLabel
Cost-utility of the 21-gene re ...... d node-positive breast cancer.
@en
Cost-utility of the 21-gene re ...... d node-positive breast cancer.
@nl
P2093
P2860
P1476
Cost-utility of the 21-gene re ...... d node-positive breast cancer.
@en
P2093
Daniel Rayson
Lynn Lethbridge
Nathan W D Lamond
Tallal Younis
P2860
P2888
P304
P356
10.1007/S10549-012-1989-5
P407
P577
2012-02-24T00:00:00Z